Knight Capital Group’s Pacific Biosciences PACB Stock Holding History

Knight Capital Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$27K	Buy	+10,576	New	+$26.3K	﹤0.01%	3149

Other funds holding PACB

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Fuller & Thaler Asset Management

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Knight Capital Group's PACB Position: Q2 2013 in Review

Knight Capital Group opened a new position in Pacific Biosciences (PACB) in Q2 2013: 10,576 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #3149 among its holdings.

71 funds tracked by Wall St. Rank hold PACB as of Q2 2013.

Knight Capital Group held 10,576 shares of Pacific Biosciences worth $27K as of Q2 2013.
Pacific Biosciences was a new Knight Capital Group position in Q2 2013.
Pacific Biosciences made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #3149 holding.
71 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.